Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAZA: CD38 mAb Induction and Azathioprine Maintenance for caABMR in Kidney Transplant
NCT07718308Not yet recruiting
- Sponsor
- Wujianyong
- Start
- Jul 2026
- Primary completion
- Mar 2028
01
Overview
Open-label, single-arm trial of azathioprine in chronic antibody-mediated rejection (cAMR), sponsored by Wujianyong. Primary endpoint: Slope of estimated glomerular filtration rate decline at 28 weeks. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
azathioprine
03
Conditions
chronic antibody-mediated rejection (cAMR)
Beyond the preview
Go deeper on NCT07718308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07718308.